The suspect device has not been returned to olympus for evaluation.The investigation is in process.The literature article https://doi.Org/10.1016/j.Gie.2022.10.038, provided for additional information.Once the investigation has been completed, a supplemental report will be submitted with device evaluation results.
|
Olympus medical systems corp.(omsc) received a literature titled "endoscopic ultrasound-guided antegrade stent placement in patients with failed ercp as a modality of preoperative and palliative biliary drainage." literature summary this retrospective review study aims to assess the outcomes of eus-guided antegrade biliary drainage (eus-ag) in patients with failed ercp or inaccessible papilla in both the palliative setting and as a modality of preoperative biliary drainage.A total of 54 patients were included.Most common primary cancer was pancreatic cancer in 42.1% (23/54) patients.Indication was palliative in 34 (62.9%) patients and pbd in 20 (37%) patients.Level of block was distal in 35 (64.8%) and proximal in 19 (35.1%) patients.Technical success of eus-ag was 88.7% (47/53).Clinical success was seen in 95.7% (45/47) patients.No severe adverse events were reported related to the procedure.Out of 20 patients who underwent endoscopic-ultrasound biliary drainage (eus-bd) as a modality of pbd, 19 had a distal cbd stricture, while one had a bismuth type i hilar block.Technical success was achieved in 19 (95%) patients.Eus-ag is safe and "effective" after failed ercp in both preoperative and palliative setting.Type of adverse events/number of patients: event1: severe intrahepatic cholestasis - 2 patients, event2: postprocedure cholecystitis - 1 patient, event3: mild pancreatitis - 1 patient, event4: self-limiting pneumoperitoneum - 2 patients, event5: died of advanced disease within 3 months - 7 patients, event6: expired due to pulmonary thromboembolism - 1 patient event7: leak at the pancreaticojejunostomy site - 1 patient, event8: bleeding in the surgical bed needing re-exploration.Despite controlling the bleeding, the patient subsequently developed multiorgan dysfunction and expired - 1 patient, this literature article requires 2 reports.The related patient identifiers are as follows: (b)(6) reports the device gf-uct180 for events 2, 7, (b)(6) reports the device gf-uct180 for events 6, 8.This medwatch report is for (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation and correction to the initial with information inadvertently left out.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse events cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.Olympus will continue to monitor field performance for this device.
|